DexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date.

Dexcom released its 2026 State of Type 2 Report highlighting significant gaps in CGM awareness and reimbursement access, with 55% of Type 2 diabetes patients having limited knowledge of the technology. However, the report reveals substantial growth opportunities as 58% of Type 2 patients on GLP-1 medicines use CGM, and a majority are open to CGM when recommended alongside GLP-1 therapy. Competitors Abbott Laboratories and MiniMed are also expanding their CGM portfolios with innovative features and sensor technologies.

ViCentra announced real-world data from 3,918 adults showing its Kaleido insulin patch pump system achieved 72.2% median time in range with minimal hypoglycemia (0.21% time below 54 mg/dL) and low glycemic variability (28.7% coefficient of variation) across Germany, the Netherlands, and France. The system, integrated with Diabeloop's DBLG1 algorithm and Dexcom G6, demonstrated strong clinical performance in routine use with high user engagement.

DexCom (DXCM), a medical device company specializing in continuous glucose monitoring systems, receives a #3 (Hold) rating from Zacks with a VGM Score of B. The company shows strong growth prospects with a Growth Style Score of A and forecasted year-over-year earnings growth of 26.3%. Seven analysts have revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $2.64 per share and an average earnings surprise of +11.4%.

A $1,000 investment in DexCom (DXCM) made 10 years ago in August 2016 would be worth $3,981.59 as of August 31, 2026, representing a 298.16% gain. This significantly outperformed the S&P 500's 255.54% gain over the same period. DexCom, a medical device company specializing in continuous glucose monitoring systems, reported 2025 revenues of $4.66 billion (up 16% YoY) and adjusted EPS of $2.09 (up 27.4% YoY). Analysts remain optimistic about future growth despite competitive market pressures.

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.

The healthcare sector is rebounding after a lackluster start to 2026, driven by rotation from tech and stabilizing costs. Three stocks are leading the rally: Eli Lilly (up 11% in a month) on strong GLP-1 drug sales and new oral pill approval; Humana (up 18% in a month) as medical utilization moderates and margins widen; and DexCom (up 15% in a month) expanding into non-insulin Type 2 diabetes markets with landmark trial data.

The FDA cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children ages 2 and older who do not use insulin, marking the first OTC continuous glucose monitor authorized for this pediatric population. The device tracks glucose levels every 15 minutes and each sensor lasts up to 15 days. The clearance was based on clinical studies and real-world evidence. Dexcom shares were down 2.2% at the time of publication.

The global non-invasive blood glucose monitoring devices market is projected to grow from USD 34.86 million in 2024 to USD 340.49 million by 2034, with a CAGR of 25.60%. Growth is driven by rising diabetes prevalence, increasing demand for painless monitoring, and technological advancements in wearables and optical sensing. Spectroscopy technology and homecare segments are expected to lead the market, while North America will dominate regionally.

DexCom outlined its 2030 growth strategy, projecting organic revenue growth exceeding 10% annually and targeting adjusted gross profit margins of 67-69%. The company also announced a new $1 billion share repurchase program and agreed with Elliott Investment Management to appoint two new independent directors with MedTech expertise. DexCom beat Q1 earnings expectations with adjusted EPS of 56 cents versus consensus of 47 cents.

Marc Lichtenfeld, Chief Income Strategist at the Oxford Club, identifies three stocks to sell this May: DexCom faces declining growth and competitive pressure from Abbott's FreeStyle Libre; Colgate-Palmolive offers limited upside with flat performance and valuation concerns; Oracle carries significant balance sheet risks with $250 billion in undisclosed lease commitments and projected negative free cash flow. The analysis follows the historical "sell in May and go away" pattern, where S&P 500 averages only 2% gains from May through October versus 7% from November to April.

Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains. With 84% of companies beating earnings expectations and 27% earnings growth, selective investing in fundamentally strong companies could outperform. The article highlights two healthcare stocks—DexCom and ResMed—as well-positioned to deliver significant upside potential despite trading below analyst price targets.